vs

Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Research Solutions, Inc. (RSSS). Click either name above to swap in a different company.

Research Solutions, Inc. is the larger business by last-quarter revenue ($11.8M vs $10.7M, roughly 1.1× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 4.6%, a 18.9% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -1.0%). Over the past eight quarters, Research Solutions, Inc.'s revenue compounded faster (-1.3% CAGR vs -13.2%).

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

Jacobs Solutions Inc. is an American international technical professional services firm based in Dallas. The company provides engineering, technical, professional, and construction services as well as scientific and specialty consulting for a broad range of clients globally, including companies, organizations, and government agencies. Jacobs has consistently ranked No. 1 on both Engineering News-Record (ENR)'s 2018, 2019, 2020, 2021, 2022, and 2023 Top 500 Design Firms and Trenchless Technolo...

ABUS vs RSSS — Head-to-Head

Bigger by revenue
RSSS
RSSS
1.1× larger
RSSS
$11.8M
$10.7M
ABUS
Growing faster (revenue YoY)
ABUS
ABUS
+523.2% gap
ABUS
522.2%
-1.0%
RSSS
Higher net margin
ABUS
ABUS
18.9% more per $
ABUS
23.5%
4.6%
RSSS
Faster 2-yr revenue CAGR
RSSS
RSSS
Annualised
RSSS
-1.3%
-13.2%
ABUS

Income Statement — Q2 FY2025 vs Q2 FY2026

Metric
ABUS
ABUS
RSSS
RSSS
Revenue
$10.7M
$11.8M
Net Profit
$2.5M
$546.9K
Gross Margin
52.4%
Operating Margin
13.9%
6.3%
Net Margin
23.5%
4.6%
Revenue YoY
522.2%
-1.0%
Net Profit YoY
112.7%
127.6%
EPS (diluted)
$0.01
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABUS
ABUS
RSSS
RSSS
Q4 25
$11.8M
Q3 25
$12.3M
Q2 25
$10.7M
$12.4M
Q1 25
$12.7M
Q4 24
$11.9M
Q3 24
$12.0M
Q2 24
$12.1M
Q1 24
$12.1M
Net Profit
ABUS
ABUS
RSSS
RSSS
Q4 25
$546.9K
Q3 25
$749.4K
Q2 25
$2.5M
$2.4M
Q1 25
$216.5K
Q4 24
$-2.0M
Q3 24
$669.0K
Q2 24
$-2.8M
Q1 24
$76.3K
Gross Margin
ABUS
ABUS
RSSS
RSSS
Q4 25
52.4%
Q3 25
50.6%
Q2 25
51.0%
Q1 25
49.5%
Q4 24
48.9%
Q3 24
47.9%
Q2 24
46.5%
Q1 24
45.2%
Operating Margin
ABUS
ABUS
RSSS
RSSS
Q4 25
6.3%
Q3 25
7.8%
Q2 25
13.9%
9.7%
Q1 25
4.4%
Q4 24
0.8%
Q3 24
5.4%
Q2 24
5.5%
Q1 24
0.7%
Net Margin
ABUS
ABUS
RSSS
RSSS
Q4 25
4.6%
Q3 25
6.1%
Q2 25
23.5%
19.0%
Q1 25
1.7%
Q4 24
-16.6%
Q3 24
5.6%
Q2 24
-23.3%
Q1 24
0.6%
EPS (diluted)
ABUS
ABUS
RSSS
RSSS
Q4 25
$0.02
Q3 25
$0.02
Q2 25
$0.01
$0.08
Q1 25
$0.01
Q4 24
$-0.07
Q3 24
$0.02
Q2 24
$-0.09
Q1 24
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABUS
ABUS
RSSS
RSSS
Cash + ST InvestmentsLiquidity on hand
$37.4M
$12.3M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$83.0M
$17.2M
Total Assets
$103.3M
$44.2M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABUS
ABUS
RSSS
RSSS
Q4 25
$12.3M
Q3 25
$12.0M
Q2 25
$37.4M
$12.2M
Q1 25
$9.9M
Q4 24
$7.7M
Q3 24
$6.9M
Q2 24
$6.1M
Q1 24
$4.2M
Total Debt
ABUS
ABUS
RSSS
RSSS
Q4 25
Q3 25
Q2 25
$0
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ABUS
ABUS
RSSS
RSSS
Q4 25
$17.2M
Q3 25
$15.6M
Q2 25
$83.0M
$13.9M
Q1 25
$11.2M
Q4 24
$11.1M
Q3 24
$12.8M
Q2 24
$11.7M
Q1 24
$14.1M
Total Assets
ABUS
ABUS
RSSS
RSSS
Q4 25
$44.2M
Q3 25
$45.5M
Q2 25
$103.3M
$46.1M
Q1 25
$45.2M
Q4 24
$42.8M
Q3 24
$41.4M
Q2 24
$41.9M
Q1 24
$40.8M
Debt / Equity
ABUS
ABUS
RSSS
RSSS
Q4 25
Q3 25
Q2 25
0.00×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABUS
ABUS
RSSS
RSSS
Operating Cash FlowLast quarter
$-15.7M
$1.4M
Free Cash FlowOCF − Capex
$1.4M
FCF MarginFCF / Revenue
11.7%
Capex IntensityCapex / Revenue
0.0%
0.1%
Cash ConversionOCF / Net Profit
-6.24×
2.53×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABUS
ABUS
RSSS
RSSS
Q4 25
$1.4M
Q3 25
$1.1M
Q2 25
$-15.7M
$2.3M
Q1 25
$2.9M
Q4 24
$1.0M
Q3 24
$843.1K
Q2 24
$2.0M
Q1 24
$2.0M
Free Cash Flow
ABUS
ABUS
RSSS
RSSS
Q4 25
$1.4M
Q3 25
$1.1M
Q2 25
Q1 25
$2.9M
Q4 24
Q3 24
Q2 24
$1.9M
Q1 24
$2.0M
FCF Margin
ABUS
ABUS
RSSS
RSSS
Q4 25
11.7%
Q3 25
8.8%
Q2 25
Q1 25
22.8%
Q4 24
Q3 24
Q2 24
16.0%
Q1 24
16.6%
Capex Intensity
ABUS
ABUS
RSSS
RSSS
Q4 25
0.1%
Q3 25
0.1%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
Q3 24
Q2 24
0.1%
Q1 24
0.0%
Cash Conversion
ABUS
ABUS
RSSS
RSSS
Q4 25
2.53×
Q3 25
1.48×
Q2 25
-6.24×
0.96×
Q1 25
13.36×
Q4 24
Q3 24
1.26×
Q2 24
Q1 24
26.43×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABUS
ABUS

Segment breakdown not available.

RSSS
RSSS

Transactions$6.6M56%
Platforms$5.2M44%

Related Comparisons